Payment overview · 2025
General Payments
$1,711.18
79 reported records · 24 companies
Healthcare provider profile · identity verified
Azriel Hirschfeld, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine|Hematology & Oncology · BROOKLYN, NY · NPI 1043240336
Verified facts
What the public records show
CMS Open Payments records show Azriel Hirschfeld, M.D. received $1,711.18 in general payments during 2025 across 79 reported records.
McKesson Specialty Care Distribution, LLC accounted for 14.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 28 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Enhertu, Ibrance, Opdivo.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LUPRON DEPOT as an associated drug or biological on 6475 records involving 3205 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Lupron Depot by this doctor in 2024.
ARRAY BIOPHARMA INC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported IBRANCE as an associated drug or biological on 54 records involving 52 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Ibrance by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENHERTU as an associated drug or biological on 13123 records involving 6425 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Enhertu by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported IMFINZI as an associated drug or biological on 14406 records involving 6935 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Imfinzi by this doctor in 2024.
Daiichi Sankyo Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Enhertu as an associated drug or biological on 25710 records involving 8530 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Enhertu by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Eliquis by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported OPDIVO as an associated drug or biological on 20448 records involving 6494 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Opdivo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported IBRANCE as an associated drug or biological on 11505 records involving 4934 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Ibrance by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| McKesson Specialty Care Distribution, LLC | Unresolved — no canonical attribution shown | $244.64 | 14.3% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $186.13 | 10.9% | 8 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $185.21 | 10.8% | 8 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $176.41 | 10.3% | 15 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $116.34 | 6.8% | 3 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $79.06 | 4.6% | 4 | 2025 |
| pharmaand GmbH | Unresolved — no canonical attribution shown | $72.65 | 4.2% | 6 | 2025 |
| Exelixis Inc. | Unresolved — no canonical attribution shown | $70.41 | 4.1% | 3 | 2025 |
| Stemline Therapeutics Inc. | Unresolved — no canonical attribution shown | $70.12 | 4.1% | 4 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $65.87 | 3.9% | 4 | 2025 |
| Menarini Silicon Biosystems, Inc. | Unresolved — no canonical attribution shown | $55.13 | 3.2% | 2 | 2025 |
| ARRAY BIOPHARMA INC | Unresolved — no canonical attribution shown | $50.05 | 2.9% | 2 | 2025 |
| TAIHO ONCOLOGY, INC. | Unresolved — no canonical attribution shown | $44.64 | 2.6% | 3 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $43.48 | 2.5% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $42.93 | 2.5% | 3 | 2025 |
| TOLMAR, INC. | Unresolved — no canonical attribution shown | $31.53 | 1.8% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $30.65 | 1.8% | 1 | 2025 |
| Ipsen Biopharmaceuticals, Inc | Unresolved — no canonical attribution shown | $28.59 | 1.7% | 1 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $28.04 | 1.6% | 1 | 2025 |
| BeOne Medicines USA, Inc. | Unresolved — no canonical attribution shown | $22.40 | 1.3% | 1 | 2025 |
| Verastem, Inc. | Unresolved — no canonical attribution shown | $21.55 | 1.3% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $17.59 | 1.0% | 1 | 2025 |
| Daiichi Sankyo Inc. | Unresolved — no canonical attribution shown | $14.25 | 0.8% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $13.51 | 0.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,497.25 | 76 |
| Education | $130.60 | 2 |
| Long term medical supply or device loan | $83.33 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| JEMPERLI Normalized: jemperli |
Biological | GlaxoSmithKline, LLC. | $186.13 | 8 | 2025 |
Source payment records
|
|||||
| ZEJULA Normalized: zejula |
Drug | GlaxoSmithKline, LLC. | $186.13 | 8 | 2025 |
Source payment records
|
|||||
| ERLEADA Normalized: erleada |
Drug | Janssen Biotech, Inc. | $185.21 | 8 | 2025 |
Source payment records
|
|||||
| Lenvima Normalized: lenvima |
Drug | Eisai Inc. | $176.41 | 15 | 2025 |
Source payment records
|
|||||
| KISQALI Normalized: kisqali |
Drug | Novartis Pharmaceuticals Corporation | $116.34 | 3 | 2025 |
Source payment records
|
|||||
| RUBRACA Normalized: rubraca |
Drug | TOLMAR, INC., pharmaand GmbH | $104.18 | 8 | 2025 |
Source payment records
|
|||||
| FRUZAQLA Normalized: fruzaqla |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $79.06 | 4 | 2025 |
Source payment records
|
|||||
| CABOMETYX Normalized: cabometyx |
Drug | Exelixis Inc. | $70.41 | 3 | 2025 |
Source payment records
|
|||||
| Orserdu Normalized: orserdu |
Drug | Stemline Therapeutics Inc. | $70.12 | 4 | 2025 |
Source payment records
|
|||||
| Cellsearch Normalized: cellsearch |
Device | Menarini Silicon Biosystems, Inc. | $55.13 | 2 | 2025 |
Source payment records
|
|||||
| BRAFTOVI Normalized: braftovi |
Drug | ARRAY BIOPHARMA INC | $50.05 | 2 | 2025 |
Source payment records
|
|||||
| MEKTOVI Normalized: mektovi |
Drug | ARRAY BIOPHARMA INC | $50.05 | 2 | 2025 |
Source payment records
|
|||||
| TUKYSA Normalized: tukysa |
Drug | ARRAY BIOPHARMA INC | $50.05 | 2 | 2025 |
Source payment records
|
|||||
| INQOVI Normalized: inqovi |
Drug | TAIHO ONCOLOGY, INC. | $44.64 | 3 | 2025 |
Source payment records
|
|||||
| LONSURF Normalized: lonsurf |
Drug | TAIHO ONCOLOGY, INC. | $44.64 | 3 | 2025 |
Source payment records
|
|||||
| Nubeqa Normalized: nubeqa |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $43.48 | 3 | 2025 |
Source payment records
|
|||||
| Xofigo Normalized: xofigo |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $43.48 | 3 | 2025 |
Source payment records
|
|||||
| OPDIVO Normalized: opdivo |
Biological | E.R. Squibb & Sons, L.L.C. | $33.16 | 2 | 2025 |
Source payment records
|
|||||
| IBRANCE Normalized: ibrance |
Drug | PFIZER INC. | $30.65 | 1 | 2025 |
Source payment records
|
|||||
| Onivyde Normalized: onivyde |
Drug | Ipsen Biopharmaceuticals, Inc | $28.59 | 1 | 2025 |
Source payment records
|
|||||
| Trodelvy Normalized: trodelvy |
Drug | Gilead Sciences, Inc. | $28.04 | 1 | 2025 |
Source payment records
|
|||||
| TEVIMBRA Normalized: tevimbra |
Drug | BeOne Medicines USA, Inc. | $22.40 | 1 | 2025 |
Source payment records
|
|||||
| AVMAPKI FAKZYNJA CO-PACK Normalized: avmapki fakzynja co pack |
Drug | Verastem, Inc. | $21.55 | 1 | 2025 |
Source payment records
|
|||||
| REBLOZYL Normalized: reblozyl |
Biological | E.R. Squibb & Sons, L.L.C. | $18.76 | 1 | 2025 |
Source payment records
|
|||||
| ELAHERE Normalized: elahere |
Drug | ABBVIE INC. | $17.59 | 1 | 2025 |
Source payment records
|
|||||
| TAGRISSO Normalized: tagrisso |
Drug | AstraZeneca Pharmaceuticals LP | $14.71 | 1 | 2025 |
Source payment records
|
|||||
| Enhertu Normalized: enhertu |
Drug | Daiichi Sankyo Inc. | $14.25 | 1 | 2025 |
Source payment records
|
|||||
| VERZENIO Normalized: verzenio |
Drug | Lilly USA, LLC | $13.51 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Enhertu enhertu |
2025 | Enhertu | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| IBRANCE ibrance |
2025 | Ibrance | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| OPDIVO opdivo |
2025 | Opdivo | 2024 | 47 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
54 | 17 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LUPRON DEPOT open payments reported associated product |
CMS Open Payments — General Payments 6475 supporting records · 3205 recipient NPIs · example record 1201352804 |
Lupron Depot · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| ARRAY BIOPHARMA INC Exact reporting entity; no affiliate inference |
2025 | IBRANCE open payments reported associated product |
CMS Open Payments — General Payments 54 supporting records · 52 recipient NPIs · example record 1228804288 |
Ibrance · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | ENHERTU open payments reported associated product |
CMS Open Payments — General Payments 13123 supporting records · 6425 recipient NPIs · example record 1206131386 |
Enhertu · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | IMFINZI open payments reported associated product |
CMS Open Payments — General Payments 14406 supporting records · 6935 recipient NPIs · example record 1206131578 |
Imfinzi · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Daiichi Sankyo Inc. Exact reporting entity; no affiliate inference |
2025 | Enhertu open payments reported associated product |
CMS Open Payments — General Payments 25710 supporting records · 8530 recipient NPIs · example record 1197002051 |
Enhertu · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | OPDIVO open payments reported associated product |
CMS Open Payments — General Payments 20448 supporting records · 6494 recipient NPIs · example record 1184377705 |
Opdivo · 2024 Exact normalized brand match · 1 Part D row |
47 | 13 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | IBRANCE open payments reported associated product |
CMS Open Payments — General Payments 11505 supporting records · 4934 recipient NPIs · example record 1228794164 |
Ibrance · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Ondansetron Hcl | Ondansetron Hcl/Pf | 205 | 62 |
| Leucovorin Calcium | Leucovorin Calcium | 196 | 58 |
| Irinotecan Hcl | Irinotecan Hcl | 192 | 59 |
| Famotidine | Famotidine/Pf | 189 | 59 |
| Fluorouracil | Fluorouracil | 181 | 51 |
| Dexamethasone Sodium Phosphate | Dexamethasone Sodium Phosp/Pf | 179 | 60 |
| Gemcitabine Hcl | Gemcitabine Hcl | 140 | 44 |
| Oxaliplatin | Oxaliplatin | 140 | 50 |
| Pantoprazole Sodium | Pantoprazole Sodium | 93 | 27 |
| Anastrozole | Anastrozole | 75 | 12 |
| Paclitaxel | Paclitaxel | 69 | 17 |
| Zirabev | Bevacizumab-Bvzr | 68 | 22 |
| Carboplatin | Carboplatin | 63 | 18 |
| Creon | Lipase/Protease/Amylase | 54 | 17 |
| Olanzapine | Olanzapine | 50 | 18 |
| Ondansetron Hcl | Ondansetron Hcl | 49 | 30 |
| Opdivo | Nivolumab | 47 | 13 |
| Keytruda | Pembrolizumab | 44 | suppressed |
| Furosemide | Furosemide | 38 | 16 |
| Lidocaine-Prilocaine | Lidocaine/Prilocaine | 38 | 22 |
| Letrozole | Letrozole | 36 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 35 | 11 |
| Zarxio | Filgrastim-Sndz | 35 | 17 |
| Eliquis | Apixaban | 33 | suppressed |
| Cisplatin | Cisplatin | 32 | suppressed |
| Procrit | Epoetin Alfa | 32 | 19 |
| Escitalopram Oxalate | Escitalopram Oxalate | 28 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 25 | 15 |
| Dexamethasone | Dexamethasone | 23 | 15 |
| Famotidine | Famotidine | 23 | suppressed |
| Gabapentin | Gabapentin | 23 | suppressed |
| Potassium Chloride | Potassium Chloride | 23 | 11 |
| Dexamethasone Sodium Phosphate | Dexamethasone Sodium Phosphate | 22 | 13 |
| Exemestane | Exemestane | 19 | suppressed |
| Atropine Sulfate | Atropine Sulfate | 18 | suppressed |
| Enhertu | Fam-Trastuzumab Deruxtecn-Nxki | 18 | suppressed |
| Granix | Tbo-Filgrastim | 18 | 13 |
| Nplate | Romiplostim | 18 | suppressed |
| Ondansetron Odt | Ondansetron | 18 | 13 |
| Yervoy | Ipilimumab | 18 | suppressed |
| Mvasi | Bevacizumab-Awwb | 17 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 17 | 13 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 17 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 16 | suppressed |
| Erbitux | Cetuximab | 16 | suppressed |
| Levothyroxine Sodium | Levothyroxine Sodium | 16 | suppressed |
| Olanzapine Odt | Olanzapine | 16 | suppressed |
| Tecentriq | Atezolizumab | 16 | suppressed |
| Lactulose | Lactulose | 15 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 15 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 15 | suppressed |
| Imfinzi | Durvalumab | 14 | suppressed |
| Mirtazapine | Mirtazapine | 14 | suppressed |
| Prednisone | Prednisone | 13 | suppressed |
| Cyclophosphamide | Cyclophosphamide | 12 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 12 | suppressed |
| Fosaprepitant Dimeglumine | Fosaprepitant Dimeglumine | 12 | suppressed |
| Ibrance | Palbociclib | 12 | suppressed |
| Losartan Potassium | Losartan Potassium | 12 | suppressed |
| Lupron Depot | Leuprolide Acetate | 11 | suppressed |
| Nivestym | Filgrastim-Aafi | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,711.18 · 79 records | McKesson Specialty Care Distribution, LLC | AVMAPKI FAKZYNJA CO-PACK, BRAFTOVI, CABOMETYX, Cellsearch, ELAHERE, ERLEADA, Enhertu, FRUZAQLA, IBRANCE, INQOVI, JEMPERLI, KISQALI, LONSURF, Lenvima, MEKTOVI, Nubeqa, OPDIVO, Onivyde, Orserdu, REBLOZYL, RUBRACA, TAGRISSO, TEVIMBRA, TUKYSA, Trodelvy, VERZENIO, Xofigo, ZEJULA | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Enhertu play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error